Company intelligence / Profile preview

Slingshot Therapeutics Limited

Huntingdon, Cambridgeshire, United Kingdomslingshot-accelerator.co.uk ↗

Ownership: Private
Development stage: Preclinical

Overview

Slingshot Therapeutics launched in November 2024 with £12.5 million from Syncona to build a pipeline of early-stage small molecule programs sourced from leading academic institutions. Its first asset, Apini (SSTX‑001), is preclinical and targets inflammatory diseases. The company aims to rapidly identify and advance additional programs using its centralized expertise and resources.

Therapeutic areas: Immunology
Modalities: Small molecules
Industry: Biotech

Drug pipeline

1 asset

SSTX-001

Preclinical

Partnerships

Syncona LimitedUniversity of Manchester, UK

Beyond the preview

Go deeper on Slingshot Therapeutics Limited.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Slingshot Therapeutics Limited.

Explore the full profile